Table 1 Baseline characteristics
All N = 341 | LSD N = 82 | MSD N = 116 | HSD N = 143 | P value | |
|---|---|---|---|---|---|
Age years, mean (SD) | 64.4 (14.9) | 68.4 (15.1) β | 66.9 (15.4) | 60.1 (13.2)μ | <0.05 |
Female, n (%) | 128 (37.5) | 35 (42.7) | 46 (39.7) | 47 (32.9) | 0.29 |
MAP mm Hg, mean (SD) | 111 (14.2) | 111 (14.1) | 114 (15.1) | 112 (13.5) | 0.36 |
BMI kg/m2, mean (SD) | 29.9 (6.6) | 25.3 (4.1) α, β | 28.6 (4.8) μ, | 33.7 (7.0) | <0.05 |
eGFR ml/min/1.73 m2 mean, (SD) | 17.1 (5.5) | 16.4 (4.1) | 18.0 (6.7) | 16.7 (5.2) | 0.30 |
Urine protein, g/day median, (IQR) | 1.5 (2.7) | 1.0 (2.1) α, β | 1.3 (1.9) | 1.9 (3.4) | <0.05 |
Cause of CKD, n (%) | |||||
Diabetic nephropathy | 162 (47.5) | 27 (32.9) | 50 (43.1) | 85 (59.4) | 0.06 |
Ischemic nephropathy | 61 (17.9) | 21 (25,6) | 21 (18.1) | 19 (13.3) | 0.16 |
Glomerulonephritis | 43 (12.7) | 14 (17.1) | 16 (13.8) | 13 (9.1) | 0.29 |
PCKD | 27 (8) | 8 (9.6) | 10 (8.6) | 9 (6.3) | 0.67 |
Other | 48 (14.1) | 12 (14.6) | 19 (16.4) | 17 (11.9) | 0.66 |
Comorbidities, n (%) | |||||
Diabetes | 198 (58.2) | 32 (39) | 61 (52.6) | 105 (73.4) | 0.02 |
CAD | 105 (30.8) | 20 (24.4) | 35 (30.2) | 50 (35.0) | 0.48 |
CHF | 79 (23.2) | 13 (15.9) | 22 (19) | 44 (30.8) | 0.08 |
Hypertension | 319 (93.6) | 76 (92.7) | 109 (94) | 134 (93.7) | 0.99 |
CVA | 36 (10.6) | 7 (8.5) | 12 (10.3) | 17 (11.9) | 0.78 |
Dyslilidemia | 235 (68.9) | 50 (61) | 81 (69.8) | 104 (72.7) | 0.72 |
Medications, n (%) | |||||
RAS blocker | 181 (53.1) | 40 (48.8) | 64 (55.2) | 77 (53.9) | 0.88 |
Diuretic | 219 (64.2) | 48 (58.5) | 76 (65.5) | 95 (66.4) | 0.84 |
Calcium channel blockers | 237 (69.5) | 53 (64.6) | 87 (75) | 97 (67.8) | 0.78 |
Beta blockers | 178 (52.2) | 38 (46.3) | 62 (53.4) | 78 (54.5) | 0.78 |